WO 2005/032522 PCT/US2004/032714

We claim:

- 1. A topical foam aerosol formulation comprising
- (a) an active agent or agents solubilized or dispersed in an oil and water emulsion in the absence of volatile lower alcohols; and
 - (b) a hydrofluoroalkane propellant.
- 2. The formulation of clam 1 wherein the active agent is selected from the group consisting of anti-inflammatory agents, topical anesthetics, topical antibiotics, anti-fungal agents, and combinations thereof.
- 3. The formulation of claim 2 wherein the active agent is an antiinflammatory agent.
- 4. The formulation of claim 3 wherein the anti-inflammatory agent is selected from the group consisting of alclometasone dipropionate, amcinonide, beclamethasone dipropionate, betamethasone benzoate, betamethasone dipropionate, betamethasone valerate, budesonide, clobetasol propionate, clobetasone butyrate, desonide, desoxymethasone, diflorasone diacetate, diflucortolone valerate, flumethasone pivalate, fluclorolone acetonide, fluocinolone acetonide, fluocionoide, fluocortin butyl, flucortolones, fluprednidene acetate, flurandrenolone, halcinonide, hydrocortisone, hydrocortisone acetate, hydrocortisone butyrate, methylprednisolone acetate, nometasone furoate, triamcinolone acetonide, diclofenac, ibuprofen, acetylsalicylic acid, piroxicam, ketoprofen, felbinac, benzylamine, and combinations thereof.
- 5. The formulation of claim 3 wherein the concentration of the antiinflammatory agent is from about 0.01% to 10%.
- 6. The formulation of claim 2 wherein the active agent is a topical anesthetic.
- 7. The formulation of claim 6 wherein the topical anesthetic is selected from the group consisting of lidocaine, prilocaine, bupivacaine, levobupivacaine, ropivacaine, mepivacaine, procaine, chloroprocaine, propoxycaine, hexylcaine, tetracaine, cyclomethycaine, benoxinate, butacaine, proparacaine, butamben, diperodon, phenacaine, falicaine,

WO 2005/032522 PCT/US2004/032714

dyclonine, pramoxine, dimethisoquien, benzocaine, amethocaine, dibucaine, ketocaine, propanocaine, propipocaine, and combinations thereof.

- 8. The formulation of claim 6 wherein the concentration of the anesthetic is from about 1% to about 10%.
- 9. The formulation of claim 2 wherein the active agent is an antibiotic or antifungal agent.
- 10. The formulation of claim 9 wherein the antifungal agent is selected from the group consisting of clotrimazole, econazole, ketoconazole, itraconazole, miconazole, oxiconazole, sulconazole, butenafine, naftifine, terbinafine, undecylinic acid, tolnaftate, nystatin, and sertaconazole nitrate.
- 11. The formulation of claim 9 wherein the concentration of the antifungal or antibiotic agent is from about 0.3% to 5%.
- 12. A method of making a HFA containing topical foam formulation free of volatile lower alcohols comprising
- (a) making an oil in water emulsion with a predominantly, more than 50%, aqueous phase,
- (b) either dissolving drug or drugs in the aqueous or oil phase prior to emulsification or adding non-water soluble non-oil soluble drug to the emulsion to form a dispersion in the emulsion, and
 - (c) adding an HFA to the emulsion.
- 13. A HFA containing topical foam formulation free of volatile lower alcohols produced by the method of claim 12.